CD4 and rheumatic disorder: The majority of patients in the immunocompromised group (n=92) had hematological malignancies (39/92, 42.3%), followed by rheumatic diseases (14/92,15.2%), non-rheumatic diseases with long-period glucocorticoid (13/92,14.1%), solid tumors recently treated with chemotherapeutic agents (11/92,12.0%), solid organ transplantation (11/92,12.0%), HIV infection with a CD4+ T-lymphocyte count < 200cells/ul (3/92,3.3%), and hematopoietic stem cell transplantation (HCT) (1/92,1.1%) (Figure 1).